

Clinical Oversight Review Board (CORB) Criteria for Prescribing Amivantamab (Rybrevant)

Non-Formulary **amivantamab (Rybrevant)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Patient has a diagnosis of metastatic or unresectable non-small cell lung cancer (NSCLC)
- Patient must have EGFR exon 20 insertion mutation
- Patient's NSCLC must have progressed on or after platinum-based chemotherapy

kp.org

Revised: xx/xx/xx
Effective: xx/xx/xx

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest